Cargando…

Efficacy of Buspirone Augmentation of Escitalopram in Patients with Major Depressive Disorder with and without Atypical Features: A Randomized, 8 Week, Multicenter, Open-Label Clinical Trial

OBJECTIVE: This study investigated the treatment response and cognitive enhancement effects of buspirone augmentation of escitalopram in patients with major depressive disorder (MDD), according to atypical feature subtypes of MDD. METHODS: An 8 week, randomized, parallel-controlled, open-label study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shin, Cheolmin, Ko, Young-Hoon, Shim, Se-Hoon, Kim, Ji Sun, Na, Kyoung-Sae, Hahn, Sang-Woo, Lee, Seung-Hwan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Neuropsychiatric Association 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449841/ https://www.ncbi.nlm.nih.gov/pubmed/32750760 http://dx.doi.org/10.30773/pi.2020.0017

Ejemplares similares

Efficacy and safety of generic escitalopram (Lexacure(®)) in patients with major depressive disorder: a 6-week multicenter, randomized, rater-blinded, escitalopram-comparative, non-inferiority study
por: Jeong, Jong-Hyun, et al.
Publicado: (2015)

PS78. Naturalistic, retrospective comparison between antidepressant therapy and atypical antipsychotic augmentation therapy for patients with major depressive disorder
por: Cho, Se Hoon, et al.
Publicado: (2016)

Efficacy and Safety of Escitalopram, Desvenlafaxine, and Vortioxetine in the Acute Treatment of Anxious Depression: A Randomized Rater-blinded 6-week Clinical Trial
por: Shin, Cheolmin, et al.
Publicado: (2023)

Blonanserin Augmentation of Atypical Antipsychotics in Patients with Schizophrenia-Who Benefits from Blonanserin Augmentation?: An Open-Label, Prospective, Multicenter Study
por: Woo, Young Sup, et al.
Publicado: (2016)

PS89. Influence of anxiety symptoms on improvement of neurocognitive functions in patients with major depressive disorder: A 12-week, multicenter, randomized trial of tianeptine versus escitalopram, the CAMPION study
por: Kim, Kiwon, et al.
Publicado: (2016)

PS85. Efficacy and Safety of Generic Escitalopram (Lexacure) in Patients with Major Depressive Disorder: A 6-week, Multi-center, Randomized, Rater-blinded, Escitalopram-comparative, Non-inferiority Study
por: Jeong, Jong-Hyun, et al.
Publicado: (2016)

Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in Chinese population
por: Jiang, Kaida, et al.
Publicado: (2017)

An Open-Label Rater-Blinded Randomized Trial of Vilazodone versus Escitalopram in Major Depression
por: Kumar, Pattath Narayanan Suresh, et al.
Publicado: (2022)

Reproducibility of the Efficacy of Escitalopram in Patients with Major Depression Who Had Previously Remitted with Escitalopram
por: Yoshimura, Reiji, et al.
Publicado: (2021)

Long-term Escitalopram Treatment in Korean Patients with Panic Disorder: A Prospective, Naturalistic, Open-label, Multicenter Trial
por: Choi, Kwan-Woo, et al.
Publicado: (2012)

Inhibition of Axitinib on Buspirone Metabolism in vitro and in vivo
por: Zhang, Bo-Wen, et al.
Publicado: (2022)

Efficacy and Tolerability of Paliperidone Extended-release in the Treatment of First-episode Psychosis: An Eight-week, Open-label, Multicenter Trial
por: Kang, Nam-In, et al.
Publicado: (2016)

The 5-HT1A receptor agonist buspirone improves esophageal motor function and symptoms in systemic sclerosis: a 4-week, open-label trial
por: Karamanolis, George P., et al.
Publicado: (2016)

An Interim Analysis of a Randomized, Open-Label Study of Vilazodone, Escitalopram, or Vortioxetine for Major Depressive Disorder
por: Santi, N Simple, et al.
Publicado: (2023)

The Effect of Food on the Pharmacokinetics of Buspirone After Single Administration of a Sublingual Testosterone and Oral Buspirone Combination Tablet in Healthy Female Subjects
por: Gerritsen, Jeroen, et al.
Publicado: (2020)

Acute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study
por: Lee, Seung-Hoon, et al.
Publicado: (2022)

Acute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study
por: Lee, Seung-Hoon, et al.
Publicado: (2022)

PS99. First episode depression and monotherapy with escitalopram: A 16-week, open-label, flexible-dose study
por: Ravindran, Arun V., et al.
Publicado: (2016)

Perospirone augmentation of escitalopram in the treatment of an adolescent sophophobia (fear of learning) patient
por: Miyazaki, Kensuke
Publicado: (2022)

SERTRALINE AND BUSPIRONE IN ADOLESCENT DELUSIONAL BODY DYSMORPHIC DISORDER
por: Duggal, Harpreet S., et al.
Publicado: (2001)

Evaluation of sesamol and buspirone in stress induced anxiety in mice
por: Kumar, Anil, et al.
Publicado: (2013)

Buspirone and dexmedetomidine synergistically reduce the shivering threshold in humans
por: Lenhardt, R, et al.
Publicado: (2007)

Development and Statistical Optimisation of Buspirone Hydrochloride Buccoadhesive Films
por: Nagaich, Upendra, et al.
Publicado: (2014)

Development and optimization of buspirone oral osmotic pump tablet
por: Derakhshandeh, K., et al.
Publicado: (2014)

Buspirone for the Management of Functional Dyspepsia With Rapid Gastric Emptying
por: Radetic, Mark, et al.
Publicado: (2019)

Buspirone in Autism Spectrum Disorder: A Systematic Review
por: Gupta, Nihit, et al.
Publicado: (2023)

Comparative efficacy of escitalopram in the treatment of major depressive disorder
por: Ali, Mazen K, et al.
Publicado: (2011)

Pharmacokinetics of a Prototype Formulation of Sublingual Testosterone and a Buspirone Tablet, Versus an Advanced Combination Tablet of Testosterone and Buspirone in Healthy Premenopausal Women
por: van Rooij, Kim, et al.
Publicado: (2014)

Scopolamine augmentation of a newly initiated escitalopram treatment for major depressive disorder: study protocol for a randomized controlled trial
por: Zhou, Jingjing, et al.
Publicado: (2019)

Effect of buspirone on thermal sensory and pain thresholds in human volunteers
por: Pavlaković, Goran, et al.
Publicado: (2009)

Paroxetine-induced severe sleep bruxism successfully treated with buspirone
por: Milanlıoglu, Aysel
Publicado: (2012)

Anxiolytic Effects of Buspirone and MTEP in the Porsolt Forced Swim Test
por: Lee, Kaziya M, et al.
Publicado: (2017)

Buspirone in obsessive-compulsive disorder: a potential dark horse?
por: Garg, Kabir, et al.
Publicado: (2021)

Paroxetine versus Venlafaxine and Escitalopram in Korean Patients with Major Depressive Disorder: A Randomized, Rater-blinded, Six-week Study
por: Woo, Young Sup, et al.
Publicado: (2017)

Effects of 12‐week escitalopram treatment on resting‐state functional connectivity of large‐scale brain networks in major depressive disorder
por: Zhang, Shudong, et al.
Publicado: (2023)

Effect of Escitalopram on White Blood Cells in Patients With Major Depression
por: Canan, Fatih, et al.
Publicado: (2009)

Cost-effectiveness evaluation of escitalopram in major depressive disorder in Italy
por: Mencacci, Claudio, et al.
Publicado: (2013)

Early Improvement in One Week Predicts the Treatment Response to Escitalopram in Patients with Social Anxiety Disorder: A Preliminary Study
por: Oh, Kang-Seob, et al.
Publicado: (2016)

A pilot study on improvements in attention function in major depressive disorder after 12 weeks of escitalopram monotherapy or combined treatment with agomelatine
por: Li, Zhe, et al.
Publicado: (2023)

Efficacy and safety of generic escitalopram versus Lexapro in the treatment of major depression: a multicenter double-blinded randomized controlled trial
por: Yu, Yimin, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_idhho8lfa4ucrqogdu1ijqcv5b